Every 10-Q that Xilio Therapeutics, Inc. (XLO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.
Xilio Therapeutics reported higher collaboration and license revenue, driven by its partnerships with AbbVie and Gilead. Revenue rose to $18.7M for the quarter and $31.3M for the first half of 2026, compared with $8.1M and $11.0M a year earlier, mainly from AbbVie and Gilead milestones and service revenue.
Operating expenses were $22.2M for the quarter and $48.9M for the half, with research and development up year to date as programs advanced and general and administrative slightly lower. Net loss narrowed to $6.4M for the quarter and $15.9M for the half, versus $15.8M and $29.1M in 2025.
Xilio ended June 30, 2026 with $136.0M in cash and cash equivalents and expects this to fund operations for at least twelve months. Deferred revenue from AbbVie and Gilead totaled $35.3M, and common stock warrant liabilities were $30.2M. If all outstanding Series C warrants are exercised at $10.50, the company could receive up to $36.2M in additional gross proceeds in 2026.
Xilio Therapeutics reported Q1 2026 results with collaboration and license revenue of $12.6 million and a net loss of $9.5 million. Revenue rose sharply from $2.9 million a year earlier, driven by AbbVie and Gilead agreements. Operating expenses increased to $26.8 million as the company advanced its masked immuno-oncology pipeline.
Cash and cash equivalents were $150.3 million as of March 31, 2026, plus $1.8 million of restricted cash. Xilio expects this cash, together with a $6.0 million AbbVie milestone achieved in Q2 2026, to fund operations into early 2028, excluding any additional milestones or warrant exercises.
Xilio Therapeutics (XLO) reported Q3 2025 results highlighted by a sharp rise in collaboration and license revenue to $19.1 million from $2.3 million a year ago, driven by revenue recognition from its AbbVie and Gilead agreements. The quarter included a $7.0 million cumulative catch-up tied to a $17.5 million Gilead development milestone achieved in Q3.
The company posted a net loss of $16.3 million, as a $15.4 million non-cash loss from remeasuring warrant liabilities offset improved operating performance. Year-to-date revenue reached $30.1 million, with operating expenses of $60.2 million. Cash and cash equivalents were $103.8 million at September 30, 2025, up from $55.3 million at year-end, aided by a June follow-on offering with initial gross proceeds of $50.0 million and an AbbVie equity purchase.
Deferred revenue totaled $69.3 million (AbbVie $35.3 million; Gilead $34.1 million) to be recognized as services progress. The company states that recurring losses and funding needs raise substantial doubt about its ability to continue as a going concern. If exercised in cash, Series B and C warrants from the June offering could deliver up to $100.0 million in additional gross proceeds by 2026.
Xilio Therapeutics (XLO) reported a mixed quarter with strengthened liquidity but continued operating losses that raise going concern questions. The company held $121.6 million of cash and cash equivalents and $1.8 million of restricted cash at June 30, 2025 (total $123.3 million including restricted cash). Xilio recognized $11.0 million of collaboration and license revenue in the six months ended June 30, 2025 and recorded $70.9 million of total deferred revenue related to agreements with Gilead and AbbVie.
Operating results show a $29.1 million net loss for the six months ended June 30, 2025 and an $412.9 million accumulated deficit. Management discloses that these losses and cash needs create substantial doubt about the company’s ability to continue as a going concern within twelve months. The company closed a June 2025 follow-on offering that produced $50.0 million of initial gross proceeds and issued prefunded warrants and detachable common stock warrants that could yield up to $100.0 million more if exercised. Xilio is also eligible for material contingent payments under collaborations: up to $2.1 billion from AbbVie and $592.5 million from Gilead, subject to achievement of milestones.